Biotech
-
Imugene ‘encouraged’ by data for HER2 vaccine in gastric cancer
[ad_1] Australian biotech Imugene says its HER2 vaccine hit the mark in a part 1b trial, establishing a part 2…
Read More » -
Entrada emerges with $59M to fund the delivery of biologic therapies into the cell
[ad_1] Entrada Therapeutics has debuted with a $59 million sequence A and a plan to ship biologic therapies intracellularly to…
Read More » -
Idorsia’s selatogrel hits goals in phase 2 cardiovascular trials
[ad_1] Idorsia’s P2Y12 receptor antagonist selatogrel has considerably inhibited platelet aggregation in two phase 2 trials. The major endpoint successes…
Read More » -
Sophiris slides on prostate cancer data but vows to press on
[ad_1] Sophiris Bio is adamant that it’s going to advance its lead drug topsalysin into section 3 testing, after a…
Read More » -
Oncology Venture receives positive feed-back from the FDA on approval pathway for LiPlaCis and DRP in the US Stockholm Stock Exchange:OV
[ad_1] Company NewsOncology Venture receives positive feed-back from the FDA on approval pathway for LiPlaCis and DRP in the US…
Read More » -
Lexicon pain drug advances after clearing early clinical test
[ad_1] A part 1a trial of Lexicon Pharmaceuticals’ LX9211 has met its main aims. The examine discovered the AAK1 inhibitor…
Read More » -
Roivant strikes broad pipeline pact with Daiichi
[ad_1] Roivant has secured an choice to license a stream of medication from Daiichi Sankyo. The deal is the primary…
Read More » -
International Isotopes Inc. (OTCBB:INIS) is Attracting Smart Money
[ad_1] In a simply printed Form 13, filed with the US Securities and Exchange Commission (SEC), International Isotopes Inc. (OTCBB:INIS) reported…
Read More » -
Communique from EGM in Oncology Venture A/S Stockholm Stock Exchange:OV
[ad_1] Company Announcement Communique from EGM in Oncology Venture A/S Hoersholm, Denmark, December 18, 2018 – at this time,…
Read More » -
Chugai preps filings for IL-6 drug in rare disease, chasing Soliris
[ad_1] Chugai has the optimistic part 3 knowledge it must file IL-6-targeting antibody satralizumab for approval in neuromyelitis optica spectrum…
Read More »
